ArticlePloS one2025
A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology, Clinical Features, and Outcomes of Proven Invasive Fungal Infections in Pediatric Patients.Mycopathologia · 2026Article
- Pattern-based clinical recognition of diabetes-associatedFrontiers in cellular and infection microbiology · 2026Review
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive mold diseases (IMDs) are a severe complication of immunocompromised subjects and an emerging problem among severely ill, apparently immunocompetent patients. The aim of this study was to describe the epidemiological and clinical features of IMDs in Chile.
methodsProspective study of IMD cases in children and adults from 11 reference hospitals in Chile from May 2019 to May 2021.
resultsOne hundred seventy-six cases were included, 135 in adults and 41 in children, with an overall incidence of 0.4/1,000 admissions. The median age was 10.5 years in children and 56.6 years in adults, with male gender predominance in adults (61.5% versus 41.5%, p = 0.03). Immunosuppression was the most common condition in both children and adults. However, cancer, neutropenia, and hematopoietic cell transplantation were significantly more frequent in the pediatric group. In contrast, diabetes, viral pneumonia, chronic kidney disease, and chronic obstructive pulmonary disease were significantly more frequent among adult patients. Regarding the diagnostic category, 30.1% of cases were proven, 55.7% probable and 14.2% possible. Aspergillosis was the most frequent IMD diagnosed in 75.5% of cases, followed by fusariosis in children and mucormycosis in adults. Viral pneumonia was associated in 40.3% of cases, mainly COVID-19, with aspergillosis in 87.3%. No triazole resistance was observed in Aspergillus spp.. Antifungals were prescribed in 97.2% of the patients: voriconazole 61.4%, liposomal amphotericin 20.5%, combination antifungals 11.1%, and others 6.4%. Overall survival was 68.7%, 61.4%, and 51.7% at 30, 90 and 180 days, respectively. DISCUSSION: This is the most extensive study of IMDs in Chile, evidencing an incidence of 0.4 per 1,000 admissions, with aspergillosis being the most frequent infection. Nearly 40% of cases were associated with respiratory viruses, accounting for the impact of COVID-19. Despite almost all patients starting antifungal therapy, the survival rate was poor. It is advisable to start a surveillance program of IMDs in Chile and verify the absence of azole resistance of Aspergillus spp.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.